Back to Journals » OncoTargets and Therapy » Volume 10

Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma

Total article views   Abstract views HTML views PDF downloads Totals
4,785 Dovepress* 3,409 548+ 1,272 3,957
PubMed Central* 0 828 526 828
Totals 3,409 1,376 1,798 4,785
*Since 18 January 2017
+Since July 2016

View citations on PubMed Central and Google Scholar